[NCBDDD] Birth Defects Study to Evaluate Pregnancy exposureS (BD-STEPS)
Revision of a currently approved collection
No
Regular
Approved without change
04/24/2023
12/27/2022
Previous terms continue: Approved consistent with the understanding that CDC will continue to work with SAMHSA on questions related to illicit drug use. The Agency will include the OMB control number and expiration date (as well as the burden statement) on all questionnaires and forms administered to participants in this collection. CDC will characterize the limitations given the addition of the COVID-19 vaccination question in all future publications and analyses.
table that charts list comparision
Inventory as of this Action
Requested
Previously Approved
04/30/2026
36 Months From Approved
04/30/2023
9,097
0
8,940
4,473
0
4,433
0
0
44,307
The purpose of Birth Defects Study To Evaluate Pregnancy exposureS (BD-STEPS) is to evaluate factors associated with the occurrence of birth defects and stillbirths and ultimately to work to prevent major birth defects and stillbirths associated with maternal risk factors. This Revision incorporates an additional COVID-19-related sub-study, additional COVID-19 questions, and other minor edits.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.